Dupilumab is an approved therapy for severe asthma, nasal polyposis and atopic dermatitis that inhibits IL-4 and IL-13 signaling by specifically targeting the shared IL-4Rα subunit of their respective receptor complexes40–42. Here, IL13 is linked to Nasal polyposis.